Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 4/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330403 | 0.87 | TMPRSS4 (0.55) | TMPRSS4SORT1PLAUF2F10 | |
| SCHEMBL330104 | 0.84 | SMN1; SMN2 (0.48) | TMPRSS4MAPTSMN1; SMN2 | |
| SCHEMBL29403662 | 0.84 | SMN1; SMN2 (0.48) | TMPRSS4MAPTSMN1; SMN2 | |
| SCHEMBL332059 | 0.84 | TMPRSS4 (0.49) | TMPRSS4PI4KBRIPK1 | |
| SCHEMBL330526 | 0.80 | TMPRSS4 (0.42) | TMPRSS4SORT1PLAUF2F10 | |
| SCHEMBL3278037 | 0.80 | ADORA3 (0.52) | MAPTSMN1; SMN2 | |
| SCHEMBL330258 | 0.79 | TMPRSS4 (0.43) | TMPRSS4SORT1PLAUF2F10 | |
| SCHEMBL331430 | 0.78 | MAPT (0.53) | TMPRSS4SORT1PLAUF2F10 | |
| SCHEMBL5067154 | 0.76 | NPC1 (0.58) | TMPRSS4PLAUF2F10PLAT | |
| SCHEMBL329927 | 0.75 | DHODH (0.54) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AEROMICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20180334424-A1 | METHODS | AEROMICS, INC. | 2018-11-22 | — | — | US | disclosed |
| EP-2846787-B1 | Compounds for use in the treatment of aquaporin-mediated diseases | AEROMICS INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9994514-B2 | Methods of treating cerebral edema and spinal cord edema | AEROMICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9949991-B2 | Methods of treating aquaporin-mediated conditions | AEROMICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9573885-B2 | Methods of treating cerebral edema | AEROMICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160346302-A1 | NOVEL METHODS | AEROMICS, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| EP-3065728-A1 | NOVEL METHODS | Aeromics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20150342967-A1 | METHODS | AEROMICS, INC. | 2015-12-03 | — | — | US | disclosed |
| WO-2015069948-A1 | NOVEL METHODS | AEROMICS, LLC (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133405-A1 | Methods | AEROMICS, INC. | 2015-05-14 | — | — | US | disclosed |
| EP-2846787-A2 | NEW METHODS | Aeromics LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013169939-A2 | NEW METHODS | AEROMICS, LLC (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342967-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885SORT1 2889/4885PI4KB 169/4885 |
| US-20180334424-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885SORT1 2889/4885PI4KB 169/4885 |
| US-20160346302-A1 | NOVEL METHODS | AQP4, AQP1, AQP3 | TMPRSS4 2227/4885SORT1 4016/4885PI4KB 633/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1813/4885SORT1 2595/4885PI4KB 1474/4885 |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AQP4, AQP1, AQP3 | TMPRSS4 946/4885SORT1 2896/4885PI4KB 340/4885 |
| US-20150133405-A1 | Methods | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885SORT1 2889/4885PI4KB 169/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | TMPRSS4 1444/4885SORT1 2728/4885PI4KB 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.